BioSpace News Archive

According to Vision Research Reports, the global microbial identification market size was surpassed at USD 3.68 billion in 2023 and is expected to hit around USD 11.25 billion by 2033, growing at a CAGR of 11.82% from 2024 to 2033.

The asthma and COPD drugs market size was valued at a USD 37.22 billion in 2022 and it is anticipated to reach USD 61.54 billion by 2032, with an expanding 5.01% of CAGR from 2023 to 2032.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune disease, announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share.

Azenta, Inc. announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.

According to the recent study by Astute Analytica, the U.S. liquid biopsy market is witnessing a rise a revenue from US$ 3,786.2 million in 2023 to surpass a market valuation of US$ 12,004.9 million by 2032.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.

Turnstone Biologics Corp. reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today a two-year extension of the Company’s US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small interfering ribonucleic acid (siRNA).

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.